Official Journal Health Science of Prince of Songkla University

  • Home
  • Search
  • Current
  • Archives
  • Announcements
  • Guide for Authors
  • Publication Ethics
  • Editorial Board
  • Submit
  • About
  • Contact
  • Online-first Articles
  • EVENTS
  • Review Process
Home > Vol 40, No 3 (2022) > Tantisarasart

Treatment Outcomes in Eales’ Disease with Vitreous Hemorrhage at Tertiary Center in Southern Thailand

Thada Tantisarasart, Patama Bhurayanontachai

Abstract

Objective: To assess the anatomical and functional outcomes of Eales’ disease with secondary vitreous hemorrhage after conservative treatment and/or pars plana vitrectomy (PPV).
Material and Methods: A retrospective chart review of patients, diagnosed with Eales’ disease, at Songklanagarind Hospital from January 2003 to December 2017 was performed. Thirty-two eyes, from 28 patients, with secondary vitreous hemorrhage underwent conservative treatment and/or PPV; depending on the degree of vitreous hemorrhage, clinician consideration and patient’s decision.
Results: Twenty-five eyes, with low-grade (grade 1-3) and dense (grade 4) vitreous hemorrhage, initially underwent conservative treatment; in which 64.0% achieved final best corrected visual acuity (BCVA) ≥20/70 and 56.0% achieved final BCVA ≥20/40 with complete resolution of vitreous hemorrhage. However, 8 eyes eventually required additional PPV as a result of non-resolving vitreous hemorrhage. Alternatively, 7 eyes with dense vitreous hemorrhage (grade 4) at the presentation, preferred PPV as primary treatment, which resulted in final BCVA ≥20/70 in 57.0% and final BCVA ≥20/40 in 43.0%. Post vitrectomy complications included; cataract progression (52.9%), high intraocular pressure (35.3%), epiretinal membrane (23.5%), and rhegmatogenous retinal detachment (17.6%).
Conclusion: Anatomical and functional outcomes of Eales’ disease with vitreous hemorrhage were relatively good following either conservative treatment or PPV. Each treatment option offered both advantages and disadvantages. The risks and benefits of each treatment option should be discussed with each individual patient to achieve the optimal outcome. Due to being a less invasive procedure, conservative treatment should be initially performed with close monitoring. In the minority of patients, vitrectomy still plays an important role to improve visualization and enable laser photocoagulation, despite potential risk of cataract progression.

 Keywords

conservative treatment; Eales’ disease; laser photocoagulation; outcome; pars plana vitrectomy; vitreous hemorrhage

 Full Text:

PDF

References

Das T, Pathengay A, Hussain N, Biswas J. Eales’ disease: diagnosis and management. Eye 2010;24:472–82.

Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales' disease-an update. Surv Ophthalmol 2002;47:197–214.

Saxena S, Rajasingh J, Biswas S, Kumar D, Shinohara T, Singh VK. Cellular immune response to retinal S-antigen and interphotoreceptor retinoid-binding protein fragments in Eales’ disease patients. Pathobiology 1999;67:39–44.

Gupta P, Biswas J. Further evidence of the association of latent Mycobacterium tuberculosis in Eales’ disease. Int Ophthalmol 2021;41:901–6.

Muthukkaruppan V, Rengarajan K, Chakkalath HR, Namperumalsamy P. Immunological status of patients of Eales’ disease. Indian J Med Res 1989;90:351–9.

Agrawal R, Gunasekeran DV, Gonzalez-Lopez JJ, Cardoso J, Gupta B, Addison PKF, et al. Peripheral retinal vasculitis: analysis of 110 consecutive cases and a contemporary reappraisal of tubercular etiology. Retina 2017;37:112–7.

Madhavan HN, Therese KL, Doraiswamy K. Further investigations on the association of Mycobacterium tuberculosis with Eales’ disease. Indian J Ophthalmol 2002;50:35–9.

Biswas J, Ravi RK, Naryanasamy A, Kulandai LT, Madhavan HN. Eales’ disease - current concepts in diagnosis and management. J Ophth Inflamm Infect 2013;3:11.

Pathanapitoon K, Rothova A, Apinyawasisuk S, Kunavisarut P. Clinical features and etiology of retinal vasculitis in Northern Thailand. Indian J Ophthalmol 2013;61:739-42.

Saxena S, Kumar D. New classification system-based visual outcome in Eales’ disease. Indian J Ophthalmol 2007;55:267.

Biswas J, Reesha KR, Pal B, Gondhale HP, Sitaula RK. Longterm outcomes of a large cohort of patients with Eales’ disease. Ocul Immunol Inflamma 2018;26:870–6.

El-Asrar AMA, Al-Kharashi SA. Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales’ disease). Br J Ophthalmol 2002;86:1248–51.

Patwardhan SD, Azad R, Shah BM, Sharma Y. Role of intravitreal Bevacizumab in Eales' disease with dense vitreous hmoerhage. Retina 2011;31:866–70.

Dehghan MH, Ahmadieh H, Soheilian M, Azarmina M, Mashayekhi A, Naghibozakerin J. Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales’ disease. Eur J Ophthalmol 2005;15:379-83.

Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol 2004;14:236–9.

Grillone LR LR, Gow JA. Development and implementation of a vitreous hemorrhage grading scale. Retinal Physician 2006;3:S1–8.

Kumar A, Tiwari HK, Singh RP, Verma L, Prasad N. Comparative evaluation of early vs. deferred vitrectomy in Eales’ disease. Acta Ophthalmol Scand 2000;78:77–8.

Connors D, Shah G, Blinder K, Dang S. Early versus delayed vitrectomy for nondiabetic vitreous hemorrhage. J Vitreoretin Dis 2018;2. doi: 10.1177/2474126418758771.

Khanduja S, Gupta S, Sinha S, Venkatesh P, Vohra R, Garg S. Surgical outcomes of minimally invasive vitrectomy surgery in Eales’ disease. Nep J Oph 2013;5:182–9.

Shanmugam MP, Badrinath SS, Gopal L, Sharma T. Long term visual results of vitrectomy for Eales' disease complications. Int Ophthalmol 1998;22:61-4.

DOI: http://dx.doi.org/10.31584/jhsmr.2021844

Refbacks

  • There are currently no refbacks.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

SUBMIT A PAPER

JHSMR accepts online submission through

AHR-iCON 2024

Journal Metrics


2020
Acceptance rate: 52%
2021
Acceptance rate: 27.8%
2022 (March)
Acceptance rate: 15.6%
2023 (June)
Acceptance rate: 23.6%
2024 (June)
Acceptance rate: 19%


Submission to final decision
74 days

Acceptance to publication
40 days

0.6
2024CiteScore
 
 
31st percentile
Powered by Scopus



 

 

SCImago Journal & Country Rank

About The Authors

Thada Tantisarasart
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,
Thailand

Patama Bhurayanontachai
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,
Thailand

Article Tools
Abstract
Print this article
Indexing metadata
How to cite item
Email this article (Login required)
Email the author (Login required)

Supported by

 

JHSMR now Indexed in



Scopus logo.svg






Image result for crossref





PSUMJ Homepage

Keywords COVID-19 SARS-CoV-2 Thailand Vietnam anxiety children computed tomography depression diabetes diabetes mellitus elderly knowledge mental health mortality prevalence quality of life reliability risk factors stroke treatment validity
Journal Content

Browse
  • By Issue
  • By Author
  • By Title
Font Size

Open Journal Systems